News

03

Apr
March 25, 2015 - A letter from Civil Society Organizations in Asia and Eastern Europe to the Global Fund Board in advance of its Thirty-Third Meeting regarding the role of the Global Fund in providing and scaling up access to hepatitis C treatment…read full letter

03

Apr
March 2015 – WHO published the updated working paper on Sofosbuvir as key medicine for Hep C treatment and describes the relevant patents for Sofosbuvir and providing data where these patents have been filed or granted…read more

03

Apr
WHO working paper to identify relevant patents for Daclatasvir and providing data where these patents have been filed or granted...read more

02

Apr
Regional advocacy platform for access to Hep C treatment in Asia Pacific wrote to The Secretary of the 20th Expert Committee on the Selection and Use of Essential Medicines supporting MSF’s application to include Daclatasvir in the Model List of Essential Medicines of the World Health  Organisation (WHO)...read full letter